ORVET UK
Get an alert when ORVET UK files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Confirmation statement due
2027-04-25 (in 11mo)
Last made up 2026-04-11
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£4B
USD 5,607,652,000
+208,485.4% vs 2023
Employees
—
Average over period
Profit before tax
£3B
USD 4,000,633,000
+300% vs 2023
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£76,250 | £21,679 | |
| Profit before tax | -£1,495,372,655 | £2,990,680,272 | |
| Net profit | -£1,495,372,655 | £2,990,680,272 | |
| Cash | — | — | |
| Total assets less current liabilities | -£2,011,662 | £4,192,010,167 | |
| Net assets | -£2,011,662 | £4,192,010,167 | |
| Equity | -£2,011,662 | £4,192,010,167 | |
| Average employees | — | — | |
| Wages | — | — | |
| Directors' remuneration | — | — |
Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
+208,485.4%
-£2,011,662 £4,192,010,167
-
Employees
—
Not reported
-
Operating profit
+128.4%
-£76,250 £21,679
-
Profit before tax
+300%
-£1,495,372,655 £2,990,680,272
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | 3.8% | 0.0% | |
| Interest cover | -7.29x | 0.94x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 5 times since incorporation
- ORVET UK 2009-02-17 → present
- ORVET UK UNLIMITED 2009-02-17 → 2009-02-17
- ORVET UK PLC 2009-02-17 → 2009-02-17
- ORVET UK LIMITED 2009-02-17 → 2009-02-17
- ORVET UK 1996-07-19 → 2009-02-17
- GOODFORCE SECURITY LIMITED 1996-04-19 → 1996-07-19
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors consider that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Group structure
- ORVET UK · parent
- Teva Holdco US, Inc. 100%
- Anda Holdco Corp. * 100%
- Anda Marketing, Inc. * 100%
- Anda Pharmaceuticals, Inc. * 100%
- Anda, Inc. * 100%
- Anda Puerto Rico Inc. * 100%
- Teva API, Inc. * 100%
- Teva Digital Health, Inc. * 100%
- Teva Pharmaceuticals USA, Inc. * 100%
- Actavis Holdco US, Inc. * 100%
- Actavis Laboratories UT, Inc. * 100%
- Actavis Puerto Rico Holdings Inc. * 100%
- Coventry Acquisition, LLC * 100%
- Actavis Pharma, Inc. * 100%
- Actavis Pharmaceuticals NJ, Inc. * 100%
- Watson Laboratories, Inc [Connecticut] * 100%
- Watson Pharma Private Limited * 100%
- Andrx LLC * 100%
- Actavis Laboratories FL, Inc. * 100%
- Watson Management Corporation * 100%
- Watson Therapeutics, Inc. * 100%
- Circa Pharmaceuticals West, Inc. * 100%
- Royce Research and Development Limited Partnership I * 100%
- Watson Laboratories, Inc. [Nevada] * 100%
- Actavis US Holding LLC * 100%
- Actavis LLC * 100%
- Actavis Elizabeth LLC * 100%
- Actavis Kadian LLC * 100%
- Actavis Mid Atlantic LLC * 100%
- Actavis South Atlantic LLC * 100%
- Actavis Totowa LLC * 100%
- Cobalt Laboratories LLC * 100%
- Watson Laboratories, LLC * 100%
- Watson Manufacturing Services, Inc. * 100%
- Watson Pharmaceuticals (Asia) Limited * 100%
- Changzhou Siyao Pharmaceuticals Co., Ltd. * 25%
- Watson Pharmaceuticals (China) Limited * 100%
- Med All Enterprise Consulting (Shanghai) Co., Limited * 100%
- WP Holdings, Ltd. * 100%
- Watson Pharmaceuticals International, Limited * 100%
- ANTARES PHARMA INC. * 1%
- Auspex Pharmaceuticals LLC * 100%
- Barr Pharmaceuticals, LLC * 100%
- Barr Laboratories LLC * 100%
- Barr International Services, Inc. * 100%
- PLIVA, Inc. * 100%
- Odyssey Pharmaceuticals, Inc. * 100%
- Teva Women's Health, LLC * 100%
- Teva Sales and Marketing, Inc. * 100%
- Cupric Holding Co, LLC * 100%
- Cephalon, LLC * 100%
- Anesta LLC * 100%
- Cephalon Development Corporation * 100%
- Cephalon Clinical Partners, LP * 100%
- CIMA Labs, Inc. * 100%
- East End Insurance, Ltd. * 100%
- Gecko Health Innovations, Inc. * 100%
- IVAX LLC * 100%
- IVAX Pharmaceuticals Mexico, S.A. de C.V. * 100%
- IVAX (Bermuda) Ltd. * 100%
- IVAX Argentina S.A. * 100%
- IVAX Far East, Inc. * 100%
- Sicor Inc. * 100%
- Rakepoll Holding B.V. * 100%
- Lemery S.A. de C.V. * 100%
- Sicor de México S.A. de C.V. * 100%
- TEVA Pharmaceuticals Mexico S.A. de C.V. * 100%
- UAB Teva Baltics * 100%
- Teva Parenteral Medicines, Inc. * 100%
- Teva Biopharmaceuticals USA, Inc. * 100%
- Teva Pharmaceutical Finance Company, LLC * 100%
- Teva Pharmaceutical Finance IV, LLC * 100%
- Teva Pharmaceutical Finance Netherlands III B.V. * 100%
- Teva Pharmaceutical Finance V, LLC * 100%
- Teva Pharmaceutical Finance VI, LLC * 100%
- Teva Pharmaceuticals, Inc. * 100%
- Teton Pharmaceuticals, LLC * 100%
- GeminX Pharmaceuticals Canada, Inc. * 100%
- Corporacion Medco CA * 100%
- Schein Pharmaceuticals Bermuda Limited * 100%
- Representaciones E Investigaciones Medicas SA * 0.005%
- Immobiliaria Leyfe, SA de C.V. * 0.005%
- Inter Lab Pharmaceutica, SA de C.V. * 0.005%
- Watson Laboratories S. de R.L. de C.V. * 50%
- New Caribe CFC * 100%
- Teva API Services Mexico S de RL de C.V. * 50%
- Maancirkel Holding B.V. * 100%
- Inmobiliaria Lemery, S.A. de C.V. * 100%
- Patient Services and Solutions, Inc. * 100%
- TAPI Puerto Rico, Inc. * 100%
- Teva Branded Pharmaceutical Products R&D LLC * 100%
- Teva Neuroscience, Inc. * 100%
- Teva Pharmaceuticals Panama, S.A. * 100%
- Teva Respiratory, LLC * 100%
- IVAX Laboratories Puerto Rico, Inc. * 100%
- TEVA Uruguay S.A. * 100%
- Labrys Biologics, Inc. * 100%
- MicroDose Therapeutx, Inc. * 100%
Significant events
- “During the year, the company issued 1,559,166,695 fully paid ordinary shares of USD 1.00 each to its immediate parent company, Teva UK Holdco 3 Limited.”
- “In June 2024 a series of cash transactions were undertaken to reduce the intercompany indebtedness of a number of the company's indirectly wholly-owned US subsidiaries.”
- “In August 2024 a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries.”
- “In December 2024 the company entered into a share exchange agreement with its ultimate parent company, Teva Pharmaceutical Industries Ltd.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 25 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| COOPER, Dean Michael | Director | 2018-07-12 | Sep 1972 | British |
Show 25 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CHETTLEBURGH INTERNATIONAL LIMITED | Corporate Nominee Secretary | 1996-04-19 | 1996-07-18 |
| GRAYS INN SECRETARIES LIMITED | Corporate Secretary | 1996-07-18 | 2010-04-14 |
| PINSENT MASONS SECRETARIAL LIMITED | Corporate Secretary | 2017-03-13 | 2017-03-13 |
| ANDRIESSEN, Theo Jacobus | Director | 1996-07-22 | 2014-09-09 |
| BEIGHTON, John | Director | 2002-10-31 | 2009-09-02 |
| BHATTACHARJEE, Dipankar | Director | 2009-09-02 | 2013-01-10 |
| DANIELL, Richard Gordon | Director | 2016-03-18 | 2016-09-27 |
| DANIELL, Richard Gordon | Director | 2013-01-10 | 2015-08-03 |
| GRIFFIN, Deborah | Director | 2020-05-05 | 2021-10-01 |
| HORSMAN, Peter | Director | 1997-12-16 | 2009-03-04 |
| HURVITZ, Chaim | Director | 1996-07-19 | 2002-10-31 |
| INNES, Kim | Director | 2016-09-27 | 2020-04-29 |
| KAY, Andrew George | Director | 1997-12-16 | 2002-10-31 |
| MANN, Meron | Director | 2002-10-31 | 2006-02-01 |
| NAAMAN, Asaph | Director | 2021-10-01 | 2023-06-28 |
| OLDFIELD, Stephen Philip | Director | 2015-08-03 | 2016-03-18 |
| ORESKOVIC, Tim | Director | 2014-09-09 | 2016-01-14 |
| SCHREWE, Michael | Director | 2013-03-21 | 2016-08-01 |
| SUESSKIND, Dan | Director | 1996-07-22 | 1997-12-16 |
| VRHOVEC, David | Director | 2017-04-07 | 2020-05-05 |
| WILLIAMS, Robert | Director | 2016-03-18 | 2018-06-27 |
| WILLIAMS, Robert | Director | 2009-03-04 | 2013-03-21 |
| CHETTLEBURGH'S LIMITED | Corporate Nominee Director | 1996-04-19 | 1996-07-18 |
| DWS DIRECTORS LIMITED | Corporate Nominee Director | 1996-07-18 | 1996-07-22 |
| DWS MANAGERS LIMITED | Corporate Director | 1996-07-18 | 1996-07-22 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Uk Holdco 3 Limited | Corporate entity | Shares 75–100%, Voting 75–100% | 2020-05-06 | Active |
| Teva Pharmaceuticals Industries Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2020-05-06 |
Filing timeline
Last 20 of 214 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-02-18 RESOLUTIONS Resolution
- 2025-01-16 RESOLUTIONS Resolution
- 2024-12-20 RESOLUTIONS Resolution
- 2024-12-20 RESOLUTIONS Resolution
- 2023-12-29 RESOLUTIONS Resolution
- 2022-06-29 RESOLUTIONS Resolution
- 2021-11-18 RESOLUTIONS Resolution
- 2021-11-03 RESOLUTIONS Resolution
- 2021-10-24 RESOLUTIONS Resolution
- 2021-10-24 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-07 | AA | accounts | Accounts with accounts type full | |
| 2025-04-14 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-02-18 | RESOLUTIONS | resolution | Resolution | |
| 2025-01-16 | RESOLUTIONS | resolution | Resolution | |
| 2024-12-20 | RESOLUTIONS | resolution | Resolution | |
| 2024-12-20 | RESOLUTIONS | resolution | Resolution | |
| 2024-10-09 | AA | accounts | Accounts with accounts type full | |
| 2024-04-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-12-29 | RESOLUTIONS | resolution | Resolution | |
| 2023-08-07 | AA | accounts | Accounts with accounts type full | |
| 2023-07-06 | TM01 | officers | Termination director company with name termination date | |
| 2023-04-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-01-03 | AA | accounts | Accounts with accounts type full | |
| 2022-06-29 | RESOLUTIONS | resolution | Resolution | |
| 2022-04-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2021-11-18 | RESOLUTIONS | resolution | Resolution | |
| 2021-11-03 | RESOLUTIONS | resolution | Resolution | |
| 2021-10-24 | RESOLUTIONS | resolution | Resolution | |
| 2021-10-24 | RESOLUTIONS | resolution | Resolution |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.